László Orfi

[Application of Kohonen Self-Organizing Feature Maps in QSAR of human ADMET and kinase data sets].

Bálint Hegymegi-Barakonyi, László Orfi, György Kéri, 2013, Acta pharmaceutica Hungarica.

Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods.

László Orfi, György Kéri, István Kövesdi, 2004, Mini reviews in medicinal chemistry.

Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors.

Ferenc Zsila, László Orfi, György Kéri, 2009, Current medicinal chemistry.

Acid-base profiling of imatinib (gleevec) and its fragments.

Zoltán Varga, Béla Noszál, László Orfi, 2005, Journal of medicinal chemistry.

Leads for antitubercular compounds from kinase inhibitor library screens.

Damiano Banfi, Gerardo Turcatti, László Orfi, 2010, Tuberculosis.

Signal transduction therapy with rationally designed kinase inhibitors

Doris Hafenbradl, Zoltán Horváth, László Orfi, 2006 .

Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology.

Doris Hafenbradl, Zoltán Varga, Zoltán Horváth, 2005, Assay and drug development technologies.

AXL is a potential target for therapeutic intervention in breast cancer progression.

László Orfi, György Kéri, A. Ullrich, 2008, Cancer research.

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

Ola Engkvist, Zoltán Horváth, László Orfi, 2004, Chemistry & biology.